The hubris and humility of cancer pharmacology in the post immuno-oncology era.

Lazo, John S

Lazo, John S.

Affiliation

Lazo JS; Departments of Pharmacology and Chemistry University of Virginia Charlottesville VA USA.

Pharmacol Res Perspect ; 7(6): e00527, 2019 12.

Article in En | MEDLINE | ID: mdl-31624635

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Immunotherapy/methods; Medical Oncology/methods; Neoplasms/therapy; Precision Medicine/methods; Antineoplastic Agents, Immunological/pharmacology; Antineoplastic Agents, Immunological/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Immunotherapy/trends; Medical Oncology/trends; Neoplasms/genetics; Neoplasms/immunology; Precision Medicine/trends; Treatment Outcome; Tumor Microenvironment/drug effects; Tumor Microenvironment/immunology

Key words

cancer; cancer cell lines; drug discovery; immune therapy; preclinical mouse models

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Precision Medicine / Immunotherapy / Medical Oncology / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pharmacol Res Perspect Year: 2019 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google